Protagonist Therapeutics Inc (PTGX) Receives $17.25 Consensus Price Target from Analysts

Protagonist Therapeutics Inc (NASDAQ:PTGX) has been given a consensus rating of “Buy” by the six ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $17.25.

A number of analysts recently commented on PTGX shares. Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 5th. Nomura started coverage on shares of Protagonist Therapeutics in a research note on Thursday, December 6th. They issued a “buy” rating and a $13.00 target price for the company. ValuEngine cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, BMO Capital Markets started coverage on shares of Protagonist Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $17.00 target price for the company.

Shares of NASDAQ:PTGX traded up $0.29 during trading on Friday, reaching $12.94. The stock had a trading volume of 10,861 shares, compared to its average volume of 256,460. Protagonist Therapeutics has a one year low of $5.49 and a one year high of $14.36. The stock has a market capitalization of $295.38 million, a P/E ratio of -7.43 and a beta of 2.19.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Tuesday, March 12th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The company had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.45 million. Protagonist Therapeutics had a negative return on equity of 33.94% and a negative net margin of 125.87%. Equities analysts expect that Protagonist Therapeutics will post -2.77 earnings per share for the current fiscal year.

In other news, CEO Dinesh V. Ph D. Patel sold 10,909 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $7.74, for a total transaction of $84,435.66. Following the completion of the transaction, the chief executive officer now directly owns 367,396 shares of the company’s stock, valued at approximately $2,843,645.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David Y. Liu sold 3,821 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $7.74, for a total transaction of $29,574.54. Following the transaction, the insider now directly owns 37,007 shares of the company’s stock, valued at $286,434.18. The disclosure for this sale can be found here. Insiders have sold a total of 17,570 shares of company stock valued at $136,815 over the last three months. 13.80% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of the company. Northern Trust Corp increased its holdings in shares of Protagonist Therapeutics by 17.2% during the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock valued at $234,000 after purchasing an additional 5,084 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Protagonist Therapeutics by 2.6% during the 4th quarter. Acadian Asset Management LLC now owns 256,220 shares of the company’s stock valued at $1,725,000 after purchasing an additional 6,516 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of Protagonist Therapeutics by 75.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock valued at $132,000 after purchasing an additional 8,450 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Protagonist Therapeutics by 94.3% during the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock valued at $178,000 after purchasing an additional 12,819 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Protagonist Therapeutics by 2.6% during the 3rd quarter. Vanguard Group Inc. now owns 530,495 shares of the company’s stock valued at $5,458,000 after purchasing an additional 13,341 shares in the last quarter. 59.37% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

See Also: What Factors Can Affect Return on Equity?

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.